Results for sanofi eu marketing ... translation from English to Chinese (Simplified)

their aim is to submit the first marketing authorization application by late 2005 or early 2006.
它们的目的是在2005年底或2006年初之前，提出第一份销售许可证申请书。

since the appeal of who, 35 countries have withdrawn marketing authorization for oral artemisinin-based monotherapy.
自世卫组织发出呼吁以来，35个国家已撤销了口服青蒿素单一疗法药物销售许可证。

access to the pharmaceutical test data used to obtain marketing authorization from national drug regulators is a contentious issue that relates to competition from generic pharmaceutical manufacturers.
38. 获得用于从国家药品管理部门取得上市许可的药品实验数据是个颇有争议的问题，涉及到来自普通药品制造商的竞争。

globally, 48 countries have withdrawn marketing authorization for these medicines but 9 countries continue to allow their marketing, including 7 countries in africa.
全世界有48个国家已经取消这些药品的销售权，但有9个国家继续允许销售，包括7个非洲国家。

999. in 2006, 38 medical products used as contraceptives (gestagens, oestrogen, including two progestogens) were granted marketing authorization.
999. 2006年，被用作避孕药的38种医学产品（孕酮、雌性激素，包括两种黄体内泌素类）获得了销售许可。

globally, 43 countries have withdrawn marketing authorization for oral artemisinin-based monotherapies, but 15 continue to allow their marketing, including 9 in africa.
全球范围内，43个国家已撤销了口服青蒿素单一疗法销售许可证，但15个国家依然允许其上市，其中包括9个非洲国家。

overall, the decline in sccp use within the eu is in part owing to the phasing out of production and use in germany (stolzenberg 1999; ospar 2001) and the eu marketing and use directive.
总体而言，欧盟短链氯化石蜡使用量的下滑，部分原因是德国开始逐步停止短链氯化石蜡的生产和使用（stolzenberg，1999年；《保护东北大西洋海洋环境公约》，2001年）以及欧盟的市场营销和使用指令。

overall, sccp uses have declined within the eu, in part owing to the phasing out of production and use in germany (stolzenberg 1999; ospar 2001) and the eu marketing and use directive.
总体而言，欧洲联盟中短链氯化石蜡的使用量已经下滑，部分原因是德国开始逐步停止短链氯化石蜡的生产和使用（stolzenberg，1999年；ospar，2001年）以及欧洲联盟的市场营销和使用指令。

the use of mercury preservative-containing medicines, including vaccines, plasma-derived products and eye-drops, is already subject to regulation (by medical health regulators assessing safety, efficacy and quality of medical products before granting marketing authorization/registration).
包括疫苗、血源性产品和眼药水在内的使用含汞防腐剂的药品已经纳入监管（医疗卫生监管部门在批准经销授权/注册前评估医疗产品的安全性、有效性和质量）。